Differential Effects of Fibroblast Growth Factors on Expression of Genes of the Plasminogen Activator and Insulin-like Growth Factor Systems by Human Breast Fibroblasts
暂无分享,去创建一个
[1] J. Foekens,et al. Cytokine‐regulated urokinase‐type‐plasminogen‐activator (uPA) production by human breast fibroblasts in vitro , 1999, Breast Cancer Research and Treatment.
[2] K. Cullen,et al. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors , 1998, Breast Cancer Research and Treatment.
[3] Adrian V. Lee,et al. Igf system components as prognostic markers in breast cancer , 1998, Breast Cancer Research and Treatment.
[4] G. Neufeld,et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants , 1996, Cancer and Metastasis Reviews.
[5] M. Ellis,et al. Insulin-like growth factors in human breast cancer , 2004, Breast Cancer Research and Treatment.
[6] C. Sweep,et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. , 2001, Journal of the National Cancer Institute.
[7] J. Oh,et al. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. , 2001, Cancer research.
[8] I. McCutcheon,et al. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. , 2000, Endocrine reviews.
[9] R. Baxter. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. , 2000, American journal of physiology. Endocrinology and metabolism.
[10] M. Nugent,et al. Mechanisms of fibroblast growth factor 2 intracellular processing: a kinetic analysis of the role of heparan sulfate proteoglycans. , 2000, Biochemistry.
[11] H L Chen,et al. Differential regulation of FGF-1 and -2 mitogenic activity is related to their kinetics of binding to heparan sulfate in MDA-MB-231 human breast cancer cells. , 2000, Biochemical and biophysical research communications.
[12] P. Andreasen,et al. The plasminogen activation system in tumor growth, invasion, and metastasis , 2000, Cellular and Molecular Life Sciences CMLS.
[13] D. Ribatti,et al. In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. , 1999, Journal of cell science.
[14] J. Foekens,et al. Insulin-like growth factor 1 (IGF-1) and urokinase-type plasminogen activator (uPA) are inversely related in human breast fibroblasts , 1999, Molecular and Cellular Endocrinology.
[15] R. Baxter,et al. The IGF axis and programmed cell death , 1999, Immunology and cell biology.
[16] V. Speirs,et al. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours , 1999, British Journal of Cancer.
[17] S. Shibata,et al. Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. , 1999, Laboratory investigation; a journal of technical methods and pathology.
[18] J. Foekens,et al. Clinical relevance of the urokinase plasminogen activator system in breast cancer , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[19] R. O'Connor,et al. Survival factors and apoptosis. , 1998, Advances in biochemical engineering/biotechnology.
[20] D. Hume,et al. Cooperation of two PEA3/AP1 sites in uPA gene induction by TPA and FGF-2. , 1997, Gene.
[21] C. López-Otín,et al. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. , 1997, Cancer research.
[22] J. Aparicio,et al. Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. , 1997, British Journal of Cancer.
[23] S. Mandriota,et al. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. , 1997, Journal of cell science.
[24] P. Eriksson,et al. Differential regulation of the plasminogen activator inhibitor-1 (PAI-1) gene expression by growth factors and progesterone in human endometrial stromal cells. , 1997, Molecular human reproduction.
[25] H. Höfler,et al. Clinical Impact of the Plasminogen Activation System in Tumor Invasion and Metastasis: Prognostic Relevance and Target for Therapy , 1997, Thrombosis and Haemostasis.
[26] M. Jalkanen,et al. Is the sensitivity of cells for FGF-1 and FGF-2 regulated by cell surface heparan sulfate proteoglycans? , 1997, European journal of cell biology.
[27] S. Shousha,et al. The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue. , 1997, British Journal of Cancer.
[28] A. Geurts-Moespot,et al. A Sensitive and Robust Assay for Urokinase and Tissue-Type Plasminogen Activators (Upa and Tpa) and Their Inhibitor Type I (Pai-1) in Breast Tumor Cytosols , 1997, The International journal of biological markers.
[29] S. Shousha,et al. Fibroblast growth factor 2 in breast cancer: occurrence and prognostic significance. , 1997, British Journal of Cancer.
[30] R. Bast,et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.
[31] M. Duffy,et al. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. , 1996, Enzyme & protein.
[32] B. Nielsen,et al. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[33] J. Foekens,et al. Transforming growth factor beta secretion from primary breast cancer fibroblasts , 1995, Molecular and Cellular Endocrinology.
[34] F. Bertucci,et al. Expression of fgf and fgf receptor genes in human breast cancer , 1995, International journal of cancer.
[35] P. Chambon,et al. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[36] F. Sarkar,et al. Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[37] R. Rosato,et al. Interactions between insulin-like growth factor-I (IGF-I) and the system of plasminogen activators and their inhibitors in the control of IGF-binding protein-3 production and proteolysis in human osteosarcoma cells. , 1994, Endocrinology.
[38] B. Vandenbunder,et al. Stromal expression of c-Ets1 transcription factor correlates with tumor invasion. , 1994, Cancer research.
[39] N. Brünner,et al. Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion , 1994, International journal of cancer.
[40] S. Leinster,et al. Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. , 1994, British Journal of Cancer.
[41] B. Olwin,et al. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. , 1993, The Journal of biological chemistry.
[42] L. Orci,et al. Upregulation of urokinase receptor expression on migrating endothelial cells , 1993, The Journal of cell biology.
[43] B. Nielsen,et al. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator , 1993, FEBS letters.
[44] M. Loriot,et al. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[45] D. Johnson,et al. Structural and functional diversity in the FGF receptor multigene family. , 1993, Advances in cancer research.
[46] P. Campbell,et al. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. , 1992, Endocrinology.
[47] J. Foekens,et al. Stromal influences on breast cancer cell growth. , 1992, British Journal of Cancer.
[48] G. Mavrothalassitis,et al. The human ETS1 gene: genomic structure, promoter characterization and alternative splicing. , 1991, Oncogene.
[49] P. Chambon,et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.
[50] D. Rifkin,et al. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity , 1990, The Journal of cell biology.
[51] J. Lélias,et al. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[52] F. V. Schaik,et al. Sequence of cDNA encoding human insulin-like growth factor I precursor , 1983, Nature.